Amyloid Beta-peptide 1-40 and Alzheimer's Disease

Alzheimer Disease Clinical Trial

— ADAB40  

Official title:

Utility of Amyloid Beta-peptide 1-40 Measurement in the Diagnosis of Alzheimer's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02770482
• Other study ID #: PA13050
• Status: Completed
• Phase: N/A
• Start date: June 2014
• Est. completion date: March 14, 2018

Study information

• Verified date: June 2020
• Source: CHU de Reims
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The combined measurement of Ab42 and tau protein (total and phosphorylated) in the spinal fluid has been shown to be promising in the diagnosis of Alzheimer's disease (AD), and has justified its inclusion new diagnostic criteria. However, it can sometimes yield discordant results that are not discriminant (isolated variation in Ab42 or P-181 Tau). To answer this challenge, a new marker has been developed in recent years, namely amyloid beta-peptide 1-40 (Aβ40). This marker reflects the patient's total amyloid deposits and is used to calculate the Aβ42/Aβ40 ratio. This ratio measures the relative variation of Aβ42 as compared to the total amyloid burden. Literature data on this topic are sparse and to date, no report has been published evaluating the utility of this marker in the diagnostic strategy for AD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 204
• Est. completion date: March 14, 2018
• Est. primary completion date: March 14, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients attending the Memory Clinic of Champagne-Ardennes for memory disorders, and

• Whose diagnostic work-up requires assessment of biomarkers present in the cerebrospinal fluid are considered eligible for inclusion in this study.

Exclusion Criteria:

• Patients who do not have any social security coverage will not be included.

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Biological:
• spinal fluid collection

Locations

Country	Name	City	State
France	Chu de Reims	Reims

Sponsors (1)

Lead Sponsor	Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of diagnostic certitude for AD (diagnosed cases)		six months